APO RESEARCH · REPORT
Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV)
Selected research
Industry Research
Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Research Report 2026
Market perspective
The global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) include CSL, Biotest, Beijing Tiantan Biological Products, Shanxi Kangbao Biological Product and Taibang Biologic Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market by Company
CSL
Biotest
Beijing Tiantan Biological Products
Shanxi Kangbao Biological Product
Taibang Biologic Group
Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Segment by Type
25ml
50ml
100ml
Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Segment by Application
Hopistial
Clinic
Others
Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 25ml
- 50ml
- 100ml
Applications
- Hopistial
- Clinic
- Others
Companies covered
- CSL
- Biotest
- Beijing Tiantan Biological Products
- Shanxi Kangbao Biological Product
- Taibang Biologic Group
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Size (2021-2032)
- 2.2.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales (2021-2032)
- 2.2.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Average Price (2021-2032)
- 2.3 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 25ml
- 2.3.3 50ml
- 2.3.4 100ml
- 2.4 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hopistial
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales (Units) of Manufacturers (2021-2026)
- 3.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue of Manufacturers (2021-2026)
- 3.4 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Average Price by Manufacturers (2021-2026)
- 3.5 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV), Product Type & Application
- 3.8 Global Manufacturers of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV), Established Date
- 3.9 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CSL
- 4.1.1 CSL Company Information
- 4.1.2 CSL Business Overview
- 4.1.3 CSL Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CSL Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
- 4.1.5 CSL Recent Developments
- 4.2 Biotest
- 4.2.1 Biotest Company Information
- 4.2.2 Biotest Business Overview
- 4.2.3 Biotest Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Biotest Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
- 4.2.5 Biotest Recent Developments
- 4.3 Beijing Tiantan Biological Products
- 4.3.1 Beijing Tiantan Biological Products Company Information
- 4.3.2 Beijing Tiantan Biological Products Business Overview
- 4.3.3 Beijing Tiantan Biological Products Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Beijing Tiantan Biological Products Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
- 4.3.5 Beijing Tiantan Biological Products Recent Developments
- 4.4 Shanxi Kangbao Biological Product
- 4.4.1 Shanxi Kangbao Biological Product Company Information
- 4.4.2 Shanxi Kangbao Biological Product Business Overview
- 4.4.3 Shanxi Kangbao Biological Product Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Shanxi Kangbao Biological Product Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
- 4.4.5 Shanxi Kangbao Biological Product Recent Developments
- 4.5 Taibang Biologic Group
- 4.5.1 Taibang Biologic Group Company Information
- 4.5.2 Taibang Biologic Group Business Overview
- 4.5.3 Taibang Biologic Group Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Taibang Biologic Group Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
- 4.5.5 Taibang Biologic Group Recent Developments
5 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Scenario by Region
- 5.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region: 2021-2032
- 5.2.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region: 2021-2026
- 5.2.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region: 2027-2032
- 5.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Region: 2021-2032
- 5.3.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Region: 2021-2026
- 5.3.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Region: 2027-2032
- 5.4 North America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Facts & Figures by Country
- 5.4.1 North America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2021-2032)
- 5.4.3 North America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Facts & Figures by Country
- 5.5.1 Europe Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2021-2032)
- 5.5.3 Europe Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Facts & Figures by Country
- 5.7.1 South America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2021-2032)
- 5.7.3 South America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Type (2021-2032)
- 6.1.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Type (2021-2032) & (Units)
- 6.1.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Market Share by Type (2021-2032)
- 6.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Type (2021-2032)
- 6.2.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue Market Share by Type (2021-2032)
- 6.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Application (2021-2032)
- 7.1.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Application (2021-2032) & (Units)
- 7.1.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Market Share by Application (2021-2032)
- 7.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Application (2021-2032)
- 7.2.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue Market Share by Application (2021-2032)
- 7.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Value Chain Analysis
- 8.1.1 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Production Mode & Process
- 8.2 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Distributors
- 8.2.3 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Customers
9 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Analyzing Market Dynamics
- 9.1 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Trends
- 9.2 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Drivers
- 9.3 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Opportunities and Challenges
- 9.4 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst